Clinical Trials Browser

Phase 3 × Active not recruiting × Plasma cell × Clear all

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT05083169 2026-03-18

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 1 FDA

Multiple Myeloma

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04512235 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT05257083 2026-03-17

CARTITUDE-6

Phase 3 Active not recruiting

Multiple Myeloma

NCT05552976 2026-03-17

SUCCESSOR-2

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT04181827 2026-03-16

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT03901963 2026-03-13

AURIGA

Phase 3 Active not recruiting

200 enrolled 12 charts

Multiple Myeloma

NCT04923893 2026-03-13

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT03844048 2026-03-06

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06045806 2026-03-05

KarMMa-9

Phase 3 Active not recruiting

Multiple Myeloma

NCT03729804 2026-03-04

(COBRA)

Phase 3 Active not recruiting

Multiple Myeloma

NCT00602641 2026-03-03

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Active not recruiting

306 enrolled 12 charts

Multiple Myeloma

NCT03480360 2026-02-19

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Phase 3 Active not recruiting

21 enrolled 19 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Lymphoma, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT05572515 2026-02-13

MajesTEC-9

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT04162210 2026-02-11

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Multiple Myeloma

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Phase 3 Active not recruiting

Multiple Myeloma

NCT03617731 2026-02-03

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Phase 3 Active not recruiting

Multiple Myeloma

NCT01208662 2026-01-22

DFCI 10-106

Phase 3 Active not recruiting

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03652064 2026-01-20

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 1 FDA

Multiple Myeloma

NCT05455320 2026-01-16

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03246529 2026-01-15

GENESIS

Phase 3 Active not recruiting

180 enrolled 22 charts

Multiple Myeloma

NCT05317416 2025-12-22

MagnetisMM-7

Phase 3 Active not recruiting

Hematologic Diseases, Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Phase 3 Active not recruiting

Multiple Myeloma

NCT01169337 2025-11-25

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Phase 3 Active not recruiting

226 enrolled 16 charts

Smoldering Multiple Myeloma

NCT00114101 2025-11-24

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Phase 3 Active not recruiting

460 enrolled 11 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT04459416 2025-10-20

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

Phase 3 Active not recruiting

299 enrolled 11 charts

LymphoidPlasma cell

Agnosia, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05556720 2025-10-03

BOOST-IC

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04071457 2025-09-15

DRAMMATIC

Phase 3 Active not recruiting

Multiple Myeloma

NCT03993912 2025-09-11

IFM2017_03

Phase 3 Active not recruiting

Multiple Myeloma

NCT01863550 2025-09-08

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Active not recruiting

Multiple Myeloma

NCT04975997 2025-07-10

EXCALIBER-RRMM

Phase 3 Active not recruiting

Multiple Myeloma

NCT00734877 2025-06-29

TT4B

Phase 3 Active not recruiting

Multiple Myeloma

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms, Recurrence

NCT06956170 2025-06-11

DREAMM 8

Phase 3 Active not recruiting

21 enrolled 9 charts

Multiple Myeloma

NCT06868667 2025-05-09

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

Phase 3 Active not recruiting

302 enrolled 10 charts

Multiple Myeloma

NCT04483739 2025-02-26

IsKia

Phase 3 Active not recruiting

Multiple Myeloma

NCT04939142 2025-02-11

BENCH

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT04096066 2025-01-15

KRdvsRd

Phase 3 Active not recruiting

Multiple Myeloma

NCT03836014 2024-12-06

CONFIRM

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03319667 2024-11-27

IMROZ

Phase 3 Active not recruiting

475 enrolled 1 FDA

Multiple Myeloma

NCT04934475 2024-11-07

MIDAS

Phase 3 Active not recruiting

Multiple Myeloma

NCT04246047 2024-10-24

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT03948035 2023-05-06

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Phase 3 Active not recruiting

Multiple Myeloma

NCT02544308 2022-12-23

IDRIS

Phase 3 Active not recruiting

Plasmacytoma

NCT03651128 2022-12-15

KarMMa-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence